Source: Annual Congress 2004 - Modern techniques bringing new insights into cystic fibrosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. L. Pukhalsky, G. V. Shmarina (Moscow, Russia). Dysregulation of systemic and local immune response in cystic fibrosis patients with chronic P. aeruginosa infection. Eur Respir J 2004; 24: Suppl. 48, 2391

Member's Comments

No comment yet.

Related content which might interest you: Changes in local and systemic inflammatory markers in cystic fibrosis patients chronically infected with Burkholderia cepacia complex Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis Year: 2020 Chronic but not intermittent infection with Pseudomonas aeruginosa is associated with global changes of the lung microbiome in cystic fibrosis Source: Eur Respir J, 50 (4) 1701086; 10.1183/13993003.01086-2017 Year: 2017 Impact of Pseudomonas aeruginosa infection on Na+ transport in airway epithelia Source: Annual Congress 2007 - The impact of viral and bacterial infection on the respiratory epithelium Year: 2007 Chronic Pseudomonas aeruginosa lung infection, but not CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis Source: Virtual Congress 2021 – Adult cystic fibrosis Year: 2021 Local immune protection mechanisms during bacterial infection of the airways in patients with interstitial lung diseases Source: Annual Congress 2009 - Mechanisms of infection: what's new? Year: 2009 Systemic quorum sensing signal molecules are biomarkers for current and future P. aeruginosa infection in cystic fibrosis patients: A longitudinal study Source: International Congress 2015 – Cystic fibrosis: assessment and treatment Year: 2015 The effect of clarithromycin on immunity of mice with chronic respiratory infection caused by P. aeruginosa Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008 Microbes mediated host innate immune response in idiopathic pulmonary fibrosis Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016 Bacterial infection and lung function in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 615s Year: 2005 Polymorphisms of the IL-10 gene and pseudomonas aeruginosa infection in patients with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 717s Year: 2006 Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006 The efficacy of early eradication therapy in prevention of chronic pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 486s Year: 2006 Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2007; 30: 286-292 Year: 2007 Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa Source: Eur Respir J 2003; 22: 503-506 Year: 2003 Community-aquired pneumonia: systemic and local inflammatory response in treatment failure Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008 Long-term evaluation of the response to aggressive treatment at the first colonization of P.aeruginosa in cystic fibrosis (CF) Source: Eur Respir J 2001; 18: Suppl. 33, 126s Year: 2001 Lack of an exaggerated inflammatory response on virus infection in cystic fibrosis Source: Eur Respir J 2012; 39: 297-304 Year: 2012